Vanda Pharmaceuticals Inc (VNDA)

NASDAQ
Currency in USD
4.49
-0.09(-1.97%)
Closed·
After Hours
4.71+0.22(+4.90%)
·
VNDA Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
VNDA is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
4.484.60
52 wk Range
3.816.46
Key Statistics
Edit
Prev. Close
4.58
Open
4.53
Day's Range
4.48-4.6
52 wk Range
3.81-6.46
Volume
268.8K
Average Vol. (3m)
545.22K
1-Year Change
-26.6%
Book Value / Share
8.77
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
VNDA Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
12.67
Upside
+182.11%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

Vanda Pharmaceuticals Inc News & Analysis

Show more

Vanda Pharmaceuticals Inc Company Profile

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company’s marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson’s disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Ponvory for the treatment of psoriasis and ulcerative colitis. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) a LAI formulation to treat schizophrenia; Bysanti for the acute treatment of bipolar I disorder, schizophrenia, and major depressive disorder; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, and atopic dermatitis. The company’s pipeline products also include Imsidolimab, an IL-36R antagonist, for the treatment of generalized pustular psoriasis; VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; VPO-227 for the treatment of secretory diarrhea disorders comprising cholera; Antisense oligonucleotide molecules, including VCA-894A for the treatment of Charcot-Marie-Tooth Disease and Type 2S (CMT2S); and VGT-1849A for the treatment of polycythemia vera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Vanda Pharmaceuticals Inc SWOT Analysis


Market Valuation
Analyst price targets range from $5.21 to $18, with Cantor Fitzgerald maintaining a $13 target, suggesting potential undervaluation of Vanda's stock
Pipeline Potential
Delve into Vanda's promising pipeline, including milsaperidone for Major Depressive Disorder and tradipitant for motion sickness and gastroparesis
Product Portfolio
Explore Vanda's strategic expansion of Fanapt into the Bipolar Depression market and the relaunch of PONVORY for Multiple Sclerosis, driving potential growth
Financial Resilience
Vanda Pharmaceuticals maintains robust gross profit margins of 93.62% and a conservative beta of 0.76, indicating strong financial health and lower market volatility
Read full SWOT analysis

Vanda Pharmaceuticals Inc Earnings Call Summary for Q1/2025

  • Q1 2025 revenue of $50M missed forecast by $11M; net loss widened to $29.5M from $4.1M in Q1 2024
  • Stock fell 1.6% after-hours to $4.31; company maintains 94.31% gross profit margins and strong cash position
  • Fanapt and HETLIOZ revenues grew 14% and 4% respectively; PONVORY declined 18%
  • FY2025 revenue guidance: $210M-$250M; six products expected to be commercially available by 2026
  • CEO highlights new growth phase; CFO emphasizes significant market opportunity in psychiatry portfolio
Last Updated: 05/07/2025, 05:39 PM
Read Full Transcript

Compare VNDA to Peers and Sector

Metrics to compare
VNDA
Peers
Sector
Relationship
P/E Ratio
−6.1x−19.0x−0.5x
PEG Ratio
0.01−0.100.00
Price / Book
0.5x9.3x2.6x
Price / LTM Sales
1.3x56.6x3.1x
Upside (Analyst Target)
188.2%426.0%48.6%
Fair Value Upside
Unlock−4.3%8.9%Unlock

Analyst Ratings

2 Buy
1 Hold
0 Sell
Ratings:
3 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 12.67
(+182.11% Upside)

Earnings

Latest Release
May 07, 2025
EPS / Forecast
-0.50 / -0.02
Revenue / Forecast
50.04M / 61.02M
EPS Revisions
Last 90 days

VNDA Income Statement

People Also Watch

3.340
NRXP
-4.02%
6.860
NVTS
-4.59%
2.81
SANA
+11.51%
39.240
SMR
-7.65%

FAQ

What Is the Vanda (VNDA) Stock Price Today?

The Vanda stock price today is 4.49

What Stock Exchange Does Vanda Trade On?

Vanda is listed and trades on the Nasdaq Stock Exchange stock exchange.

What Is the Stock Symbol for Vanda?

The stock symbol for Vanda is "VNDA."

What Is the Vanda Market Cap?

As of today, Vanda market cap is 266.97M.

What Is Vanda's Earnings Per Share (TTM)?

The Vanda EPS (TTM) is -0.76.

When Is the Next Vanda Earnings Date?

Vanda will release its next earnings report on Jul 24, 2025.

From a Technical Analysis Perspective, Is VNDA a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.

How Many Times Has Vanda Stock Split?

Vanda has split 0 times.

How Many Employees Does Vanda Have?

Vanda has 368 employees.

What is the current trading status of Vanda (VNDA)?

As of Jun 18, 2025, Vanda (VNDA) is trading at a price of 4.49, with a previous close of 4.58. The stock has fluctuated within a day range of 4.48 to 4.60, while its 52-week range spans from 3.81 to 6.46.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.